Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Amivantamab plus lazertinib vs osimertinib in first-line <i>EGFR</i>-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study.
PaperCitations, authors & open-access status
Amivantamab plus lazertinib vs osimertinib in first-line <i>EGFR</i>-mutant advanced non-small cell lung cancer (NSCLC) with biomarkers of high-risk disease: A secondary analysis from the phase 3 MARIPOSA study. is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 17 citations, 2024 year and closed oa status.
17
Citations
2024
Year
closed
OA Status